Literature DB >> 33421372

Organizational Readiness for Lung Cancer Screening: A Cross-Sectional Evaluation at a Veterans Affairs Medical Center.

Lucy B Spalluto1, Jennifer A Lewis2, Deonni Stolldorf3, Vivian M Yeh4, Carol Callaway-Lane5, Renda Soylemez Wiener6, Christopher G Slatore7, David F Yankelevitz8, Claudia I Henschke9, Timothy J Vogus10, Pierre P Massion11, Drew Moghanaki12, Christianne L Roumie13.   

Abstract

OBJECTIVES: Lung cancer has the highest cancer-related mortality in the United States and among Veterans. Screening of high-risk individuals with low-dose CT (LDCT) can improve survival through detection of early-stage lung cancer. Organizational factors that aid or impede implementation of this evidence-based practice in diverse populations are not well described. We evaluated organizational readiness for change and change valence (belief that change is beneficial and valuable) for implementation of LDCT screening.
METHODS: We performed a cross-sectional survey of providers, staff, and administrators in radiology and primary care at a single Veterans Affairs Medical Center. Survey measures included Shea's validated Organizational Readiness for Implementing Change (ORIC) scale and Shea's 10 items to assess change valence. ORIC and change valence were scored on a scale from 1 to 7 (higher scores representing higher readiness for change or valence). Multivariable linear regressions were conducted to determine predictors of ORIC and change valence.
RESULTS: Of 523 employees contacted, 282 completed survey items (53.9% overall response rate). Higher ORIC scores were associated with radiology versus primary care (mean 5.48, SD 1.42 versus 5.07, SD 1.22, β = 0.37, P = .039). Self-identified leaders in lung cancer screening had both higher ORIC (5.56, SD 1.39 versus 5.11, SD 1.26, β = 0.43, P = .050) and change valence scores (5.89, SD 1.21 versus 5.36, SD 1.19, β = 0.51, P = .012). DISCUSSION: Radiology health professionals have higher levels of readiness for change for implementation of LDCT screening than those in primary care. Understanding health professionals' behavioral determinants for change can inform future lung cancer screening implementation strategies. Published by Elsevier Inc.

Entities:  

Keywords:  Implementation science; lung cancer; lung cancer screening; organizational readiness; veteran

Mesh:

Year:  2021        PMID: 33421372      PMCID: PMC8180484          DOI: 10.1016/j.jacr.2020.12.010

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   6.240


  25 in total

1.  Overview of the Veterans Health Administration (VHA) Quality Enhancement Research Initiative (QUERI).

Authors:  Lynn McQueen; Brian S Mittman; John G Demakis
Journal:  J Am Med Inform Assoc       Date:  2004-06-07       Impact factor: 4.497

2.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

3.  Lung Cancer Screening With Low-Dose Computed Tomography in the United States-2010 to 2015.

Authors:  Ahmedin Jemal; Stacey A Fedewa
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 31.777

4.  Readiness for Implementation of Lung Cancer Screening. A National Survey of Veterans Affairs Pulmonologists.

Authors:  Melissa H Tukey; Jack A Clark; Rendelle Bolton; Michael J Kelley; Christopher G Slatore; David H Au; Renda Soylemez Wiener
Journal:  Ann Am Thorac Soc       Date:  2016-10

5.  Initial experience with a free, high-volume, low-dose CT lung cancer screening program.

Authors:  Brady J McKee; Andrea B McKee; Sebastian Flacke; Carla R Lamb; Paul J Hesketh; Christoph Wald
Journal:  J Am Coll Radiol       Date:  2013-04-26       Impact factor: 5.532

6.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

7.  Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.

Authors:  Harry J de Koning; Carlijn M van der Aalst; Pim A de Jong; Ernst T Scholten; Kristiaan Nackaerts; Marjolein A Heuvelmans; Jan-Willem J Lammers; Carla Weenink; Uraujh Yousaf-Khan; Nanda Horeweg; Susan van 't Westeinde; Mathias Prokop; Willem P Mali; Firdaus A A Mohamed Hoesein; Peter M A van Ooijen; Joachim G J V Aerts; Michael A den Bakker; Erik Thunnissen; Johny Verschakelen; Rozemarijn Vliegenthart; Joan E Walter; Kevin Ten Haaf; Harry J M Groen; Matthijs Oudkerk
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 91.245

Review 8.  Low-dose computed tomography screening for lung cancer in a clinical setting: essential elements of a screening program.

Authors:  Brady J McKee; Andrea B McKee; Andrea Borondy Kitts; Shawn M Regis; Christoph Wald
Journal:  J Thorac Imaging       Date:  2015-03       Impact factor: 3.000

9.  Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science.

Authors:  Laura J Damschroder; David C Aron; Rosalind E Keith; Susan R Kirsh; Jeffery A Alexander; Julie C Lowery
Journal:  Implement Sci       Date:  2009-08-07       Impact factor: 7.327

10.  A theory of organizational readiness for change.

Authors:  Bryan J Weiner
Journal:  Implement Sci       Date:  2009-10-19       Impact factor: 7.327

View more
  1 in total

1.  Evaluating the clinical trends and benefits of low-dose computed tomography in lung cancer patients.

Authors:  Edmund M Qiao; Rohith S Voora; Vinit Nalawade; Nikhil V Kotha; Alexander S Qian; Tyler J Nelson; Michael Durkin; Lucas K Vitzthum; James D Murphy; Tyler F Stewart; Brent S Rose
Journal:  Cancer Med       Date:  2021-09-16       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.